Stargardt Vision Loss is Tied to Age of Symptom Onset

By understanding their visual prognosis, Stargardt’s patients can make informed decisions about their daily life and long-term plans. Photo: Jim Williamson, OD. Click image to enlarge.  Inherited retinal dystrophies, such as Stargardt disease, are genetic conditions that cause progressive retinal damage. For those with Stargardt’s, management strategies such as avoiding smoking and using low vison aids, are the only currently available options.Given the lack of curative treatments, understanding how visual acuity changes over time is essential for improving patient counseling and care. In contrast to some of the existing literature, clinical observations point to a non-linear course of visual acuity decline, with rapid decline early on followed by a levelling off period. To uncover the trajectory of vision loss in Stargardt disease type 1 and provide a model for clinicians to better counsel their patients, Dutch researchers analyzed visual acuity data from medical records. They confirmed in a recent American Journal of Ophthalmology paper that visual decline throughout a Stargardt patient’s life doesn’t follow a linear pattern.The retrospective study included 327 patients with genetically confirmed Stargardt disease and modeled the natural course of visual decline in patients with early-onset (≤10 years), intermediate-onset (11 to 44 years) and late-onset (≥45 years) disease. To learn more about Stargardt disease and other IRDs, see this recent CE course. The researchers reported that the rate of decline varied by disease stage; the early-onset and late-onset groups had significantly steeper decline rates than the intermediate-onset group. Visual acuity decline was fastest in Stargardt’s patients when their vision was 20/40, while at around 20/200, the rate of decline slowed.In addition to assessing vision deterioration, the researchers sought to determine whether visual acuity could serve as a primary endpoint in clinical trials. They performed sample size calculations which showed that for a three-year clinical trial reaching 80% power, 139 patients with a visual acuity of 20/40 would be required. “The faster the decline in visual acuity, the greater the treatment effect that can be demonstrated,” the researchers explained in the study.However, given this large sample size and the narrow window to prove treatment effect, the researchers suggested the use of “alternative biomarkers such as atrophy growth on fundus autofluorescence,” which would allow for the inclusion of a broader Stargardt’s population and require fewer resources.The authors concluded in their paper that despite visual acuity’s being an unsuitable primary endpoint, knowledge of “age-of-onset dependent trajectories of visual acuity decline will help clinicians counsel their patients.”Click here for the journal source. Pas JA, Valkenburg D, Li C, et al. The visual acuity course in Stargardt disease. Am J Ophthalmol 2025. [Epub ahead of print].  This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.